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ABSTRACT BACKGROUND AND AIMS:
Sub-clinical inflammatory changes are commonly described in long-term transplant recipients undergoing protocol liver biopsies.
The pathogenesis of these lesions remains unclear. The aim of the study was to identify the key molecular pathways driving progressive sub-clinical inflammatory liver allograft damage.
PATIENTS AND METHODS: All liver recipients followed at Hospital Clínic
Barcelona who were >10 years post-transplant were screened to participate in the study. Patients with recurrence of underlying liver disease, biliary or vascular complications, chronic rejection, and abnormal liver function tests were excluded. Sixty-seven patients agreed to participate and underwent blood and serological tests, transient elastography and a liver biopsy. Transcriptome profiling was performed on RNA extracted from 49 out of the 67 biopsies employing a whole genome next generation sequencing platform. Patients were followed for a median of 6.8 years following the index liver biopsy.
RESULTS:
Median time since transplantation to liver biopsy was 13 years (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The most frequently observed histological abnormality was portal inflammation with different degrees of fibrosis, present in 45 biopsies (67%).
Two modules of 102 and 425 co-expressed genes were significantly correlated with portal inflammation, interface hepatitis and portal fibrosis. These modules were enriched in molecular pathways known to be associated with T cell mediated rejection. Liver allografts showing the highest expression levels for the two modules recapitulated the transcriptional profile of biopsies with clinically apparent rejection and developed progressive damage over time, as assessed by non-invasive markers of fibrosis.
CONCLUSIONS:
A large proportion of long-term surviving adult liver transplant recipients exhibit subclinical histological abnormalities whose expression profile closely resembles T cell mediated rejection and that may result in progressive allograft damage.
Lay summary:
A large proportion of long-term surviving adult liver transplant recipients exhibit subclinical histological abnormalities. Transcriptome profiling of liver tissue showed an expression profile that closely resembles T cell mediated rejection. Liver allografts showing the highest expression levels of rejection-related genes developed progressive damage over time.
INTRODUCTION
Routine serum markers of liver injury such as aspartate and alanine aminotransferases (AST, ALT), gamma-glutamyl-transpeptidase (GGT) or alkaline phosphatase (AP) are known to be insensitive and nonspecific indicators of allograft rejection in liver transplantation (LT) [1, 2] . Despite this, the long-term management of LT recipients continues to rely on a combination of serum liver biochemistry tests and calcineurin inhibitor pharmacokinetic markers. The performance of protocol, or surveillance, liver biopsies has been proposed as a more accurate strategy to assess graft function and potentially to personalize the use of immunosuppression [3] [4] [5] . This is based on a multiplicity of studies showing that a very large proportion of patients with normal liver biochemistry tests exhibit clinically significant histological lesions, with chronic hepatitis not attributable to recognizable causes such as viral infection or autoimmune hepatitis being the most frequently described abnormality [1, [6] [7] [8] .
The clinical utility of protocol liver biopsies, however, remains contentious [5] , and as a result they are not performed in the vast majority of adult liver transplant programs. The controversy stems from an incomplete understanding of the natural history and pathogenesis of the so-called idiopathic inflammatory lesions [2, 9] . This is due to the paucity of prospective clinical studies and the lack of in-depth studies comparing the molecular signatures of these lesions with those of well-characterized histological phenotypes.
Employing microarray and real-time PCR analyses, we previously reported that it is possible to identify transcriptional signatures of acute cellular rejection in blood and liver tissue specimens of LT recipients [10, 11] . Importantly, these signatures can be detected even in the midst of the noise caused by other forms of chronic inflammation, such as that induced by hepatitis C virus (HCV).
We anticipated that a similar strategy could provide a clue as to the pathogenesis of idiopathic fibro-inflammatory lesions in long-term surviving adult liver transplant recipients. To confirm this premise, we conducted a prospective clinical study in which we approached all surviving LT recipients transplanted at Hospital Clinic Barcelona between 1988 and 1999 without previously diagnosed allograft lesions, and performed liver biopsy, transient elastrography, and next generation sequencing transcriptional studies.
PATIENTS AND METHODS

Patient population
Between December 2007 and December 2009 we screened all patients who had undergone LT at Hospital Clínic Barcelona between 1988 and 1999 and who remained alive and had been followed-up for more than 10 years after transplantation. Exclusion criteria were: 1) diagnosis of de novo or recurrent liver disease after transplantation, including HCV-related hepatitis; 2) elevation in AST, ALT or AP ≥2 fold above the upper limit of normality (isolated GGT increases were not considered an exclusion criteria [n=18]); 3) T cell-mediated rejection within 1 year of the inclusion in the study; 4) contraindications for a liver biopsy; 5) severe extra-hepatic co-morbidities ( Figure 1 ). All consented patients underwent a protocol liver biopsy and collection of a blood specimen.
Patients included in the study were followed-up until death, re-transplantation, lost to follow-up or December 2017.
All patients signed an informed consent. The study was approved by the ethical committee at Hospital Clínic Barcelona.
Laboratory tests and fibrosis evaluation
The following tests were performed at the time of inclusion: liver tests (serum AST, ALT, GGT, AP, total bilirubin, INR); platelet count; serologies for hepatitis B (surface antigen HBsAg, anti-core antibodies), hepatitis C, and hepatitis E (IgG anti-hepatitis E antibodies and RNA) viruses; and serum autoantibodies (anti-nuclear antibodies ANA, anti-smooth muscle antigen SMA, anti-liverkidney microsomal antibodies anti-LKM1/2). Liver tests and platelet counts were also analyzed at the last follow-up visit. Indirect fibrosis scores (APRI and FIB-4) were calculated using the standard formulas at the time of inclusion and at the last follow-up [12, 13] . In addition, 30 patients underwent a liver stiffness Human Gene Expression Kit (Thermo Fisher), and barcoded using Ion Express barcodes. cDNA library quality was assessed using the Agilent® 2200
Statistical analysis
TapeStation System and the High Sensitivity D1000 ScreenTape System 
Analysis of gene expression data
To explore the correlation patterns among genes across the RNASeq data derived from the 49 protocol biopsies we employed the Weighted Gene Correlation Network Analysis (WGCNA) software package available from R [16] . To perform WGCNA, correlations between all pairs of genes in the expression dataset were quantified and transformed into measures of connection strength by emphasizing strong correlations and minimizing the noise in the pairwise measurements. A hierarchical clustering algorithm was then used to identify modules of highly interconnected genes. Next, to reduce multi-dimensionality, consensus eigengenes were defined for each module and used to relate the modules to external data (e.g. clinical traits).
The statistical significance of a priori defined sets of genes representing biological pathways on the whole transcriptional dataset, which included the 49 protocol biopsies plus the 18 for-cause biopsies, was computed employing To interrogate whether biopsies exhibiting idiopathic inflammatory lesions were likely to correspond to unrecognized forms of rejection, we re-analyzed a liver tissue microarray dataset derived from two immunosuppression withdrawal trials previously reported by our group, which contained expression data from 20 pairs of liver biopsies obtained before drug weaning was initiated and at the time of rejection [11] . A gene classifier of T cell mediated rejection was identified using Predictive Analysis of Microarrays (PAM). Of note, 7 of the 20 biopsy pairs were obtained from patients who had chronic hepatitis due to hepatitis C virus at the time of initiating drug withdrawal [11] . All samples were analyzed together to be able to develop classifiers that would identify rejection on top of underlying inflammatory lesions. The diagnostic accuracy of the resulting rejection-associated signature was evaluated by 4-fold crossvalidation, in which the original sample is randomly partitioned into 4 equal size subsamples. Of the 4 subsamples, a single subsample is retained as the validation data for testing the model, and the remaining 4-1 sub-samples are used as training data, and the procedure is repeated 40 times.
RESULTS
Patients' characteristics
Between 
Histological evaluation
The results of the central histological analysis are shown in Table 2 Table 2 ). In contrast, among the genes contained in the Cyan module we identified an over-representation of KEGG canonical pathways known to be regulated by IFNγ, as well as ATAGC PBT gene sets previously reported to be associated with T cell mediated rejection (Supplementary Table   3 ). These results suggested a potential link between active portal inflammation, fibrosis and T cell mediated rejection. Table 4 ) . We interrogated the RNASeq expression dataset from the protocol biopsy set and noted a significant correlation between the eigengenes of the group of 13 genes and those of the Cyan and Pink gene expression modules ( Figure 3C ).
To better understand the biological implications of the changes in the expression of these two modules, we decided to concentrate on those samples exhibiting extreme transcriptional phenotypes. To do so, we assigned biopsies into 2 groups, Cyan&Pink_High and Cyan&Pink_Low, according to whether their expression levels were above or below the median level of expression for both modules. We then compared the enrichment in rejection-associated gene sets between the transcriptome of the Cyan&Pink_High group and the groups of post-transplant biopsies with chronic hepatitis C, early TCMR and late TCMR, employing the Cyan&Pink_Low group as the common comparator for all groups. To conduct this analysis we used the QuSAGE method, which allows direct 2-way comparisons between several groups of samples. The
Cyan&Pink_High group transcriptome was significantly enriched in a number of KEGG canonical pathways associated with allograft rejection and immunopathology (Table 3) . Furthermore, among the ATAGC PBT gene sets, In contrast, the transcriptomes of these 3 groups differed from the transcriptional profile observed in the chronic hepatitis C group, in which, with the exception of the GRIT1 and BAT gene sets, no significant enrichment in rejection-associated transcript sets was noted ( Table 3 ). The potential for progressive liver damage was investigated by quantifying the enrichment in a set of 122 genes preferentially expressed by liver stellate cells and known to be correlated with the extent of liver fibrosis and with the survival of patients with liver cirrhosis [18] . Over-representation of this gene set was only noted on the Cyan&Pink_High expression module (Table 3) .
Clinical parameters associated with liver tissue gene expression changes
We next investigated whether the transcriptional differences between the Table 5 ). Furthermore, they showed more advanced portal inflammation, interface hepatitis and portal fibrosis (Supplementary Table 5 ). At the last follow-up visit, as compared to patients in the Cyan&Pink_Low group, patients from the Cyan&Pink_High group continued to have a significantly higher APRI score and in addition they exhibited higher FIB-4 fibrosis score, AST and bilirubin, and lower platelet count (Supplementary Table 5 ). To better understand the significance of the changes observed during patient follow-up, and to clarify whether Cyan&Pink group assignment exerted an effect that was independent from the changes seen at baseline, we reanalyzed the data employing a non-parametric ANCOVA adjusted by the length of the follow-up. This confirmed the significant association between
Cyan&Pink_High group assignment and the development of higher bilirubin level (p=0.0475), lower platelet count (p=0.0025), higher ALT (p=0.0124), and higher APRI score (p=0.0277), at the end of the follow-up (Table 4) .
DISCUSSION
It is now well established that subclinical chronic allograft injury is very prevalent in long-term surviving LT recipients. Previous studies have reported histological abnormalities in 5% to 90% of late protocol liver biopsies. In children, the prevalence appears to be higher higher ranging between 67% and 95% [6, 7, 21] . The reasons for this variability are not entirely clear but they are probably related to differences in the indications for transplantation, follow-up duration, immunosuppression protocols, and thresholds for liver test levels [1, 19, 20] . In most studies, portal inflammation with or without interface activity and/or fibrosis, often referred to as idiopathic post-transplant hepatitis, was the most frequent finding [6, 7, 20, 19, [21] [22] [23] [24] .
The objective of our study was to investigate the mechanisms associated with sub-clinical graft deterioration by conducting an unbiased analysis of clinical, histological, biochemical and high-throughput liver tissue transcriptional data.
In particular, we questioned whether biopsies displaying idiopathic posttransplant hepatitis corresponded to unrecognized forms of rejection. To reduce the risk of bias, provide adequate clinical context and ensure the generalizability of the observations, we designed a prospective study in which we interrogated all patients transplanted at Hospital Clinic Barcelona over a 10-year period and we conducted protocol liver biopsies in those meeting predefined inclusion/exclusion criteria.
We first employed an exploratory systems biology strategy to identify, in an unsupervised manner, the key mechanistic underpinnings of the histology lesions. This was conducted using a modular analysis that explored the correlations between groups of co-expressed genes and semi-quantitative histological scores across the whole set of liver tissue samples. Out of the 23 modules of genes identified, we selected 2 for further analyses, on the basis of their significant correlation with portal inflammation and fibrosis. By representing each of the 2 expression modules by an 'eigengene' we could show a significant correlation between the modules and a 13 gene set specific for TCMR in LT that we derived from a re-analysis of two previously published microarray studies conducted by our group [10, 11] . Furthermore, the two modules were enriched in gene sets previously identified as being associated with allograft rejection across a variety of experimental and clinical settings, which again closely resembled what is observed at the time of clinically apparent early and late TCMR.
A non-rejection related form of liver allograft inflammation (recurrent HCVinduced chronic hepatitis) also exhibited transcriptional similarities with rejection. This reflects the sharing of specific pathways of tissue injury between rejection and other inflammatory insults, and is in keeping with what has been described in kidney transplantation [25] . However, the degree of overlap observed between TCMR and HCV-induced chronic hepatitis was significantly smaller than between TCMR and the subset of protocol biopsies exhibiting high expression of the two selected modules.
Although our study lacked paired longitudinal liver biopsies and thus was not designed to evaluate the histological progression of allograft damage, the analysis of the blood tests collected over time revealed that patients with high expression of the two selected gene modules exhibited a mild but significant worsening in non-invasive markers of fibrosis, liver function and portal hypertension. This was consistent with the over-expression of a distinct set of genes known to be specific for stellate cells and whose expression in the liver tissue of non-transplant patients with chronic liver disease has been reported to be associated with liver failure and patient survival [18] . Taken together, these data suggest that idiopathic post-transplant hepatitis is likely to constitute a form of unrecognized alloimmune injury that, at least in a subset of patients, results in progressive allograft damage.
Previous studies have reported an association between circulating donorspecific anti-HLA antibodies (DSA) and subclinical liver allograft inflammatory lesions [9, [26] [27] [28] [29] . The influence of DSA on the liver tissue gene expression profile could not be explored in our study due to the lack of donor HLA information. The fact that the gene modules correlated with portal inflammation and interface activity closely resembled the transcriptome of liver TCMR would argue against a significant role for antibody-mediated rejection (ABMR) in this setting. It should be acknowledged, however, that in kidney transplantation the transcriptional profile of TCMR and ABMR are known to significantly overlap [25] , and that transcripts specific for ABMR in liver transplantation have not been defined yet. Hence, our study cannot unambiguously elucidate the relative roles of cellular and humoral alloimmunity. This will require the performance of transcriptional studies of large numbers of accurately classified TCMR and ABMR cases.
The majority of patients enrolled in the current study were on very low dose immunosuppression. This reflects the standard practice at Hospital Clinic Barcelona and was not the result of an intentional drug minimization protocol.
Our findings could be interpreted as indicating that long-term surviving liver transplant recipients are insufficiently immunosuppressed. This interpretation needs to be balanced against the significant morbidity and mortality caused by immunosuppressive medications and the fact that evidences of progressive allograft damage were only noted in a minority of the patients enrolled in our study. Hence, we would caution against the use of more aggressive immunosuppressive regimens in this patient population until randomized controlled trials investigating the risk/benefit of these regimens are conducted. In the meantime, the main practical lesson to be drawn from our data is the need to recognize the possibility of subclinical rejection in longterm surviving liver recipients with normal liver function tests, and to consider sequential surveillance liver biopsies as a tool that could potentially optimize graft and patient survival. -Recipients exhibiting subclinical lesions and high expression of rejectionassociated transcripts are at risk of developing progressive liver damage. Baseline and follow-up data are expressed as median (range).Variables were compared by a non-parametric ANCOVA. P-values correspond to the comparisons of the changes observed in the two groups, adjusted by the baseline values and the time of follow-up. # Estimated mean change (with 95% CI), adjusted for mean baseline values and mean length of follow-up
